We have a demonstrated history of developing Cost-Effectiveness Models to support health policy decisions and health technology assessments. We are exceptional in creating de novo models, adapting international models to align with country- or regulator-specific requirements, conducting independent reviews of externally developed models, and performing gap analyses. We leverage a range of software options to execute these tasks, and our deliverables always include a comprehensive report accompanying our deftly developed models.

Leverage our expertise in Early Economic Modelling to evaluate the economic feasibility of healthcare interventions in their early stages. We provide insightful cost-effectiveness of treatments under several alternative scenarios. These scenarios may draw upon anticipated outcomes from ongoing clinical trials or concluded early-phase clinical trials. Consequently, we can pinpoint crucial parameter influences and deliver well-founded pricing recommendations.

Our team specializes in crafting Budget Impact Models that offer a transparent forecast of expenditures associated with the implementation of a new intervention. These models are customised to meet the specific requirements of individual budget holders, providing valuable insights to facilitate well-informed decision-making. We have the flexibility to develop the model using various software options to align with your preferences or regulatory agency standards. Additionally, a comprehensive report accompanies the model, enhancing the depth of information provided.

Our comprehensive support spans the entire lifecycle of your project, from the initial planning phase to the publication of results. Our team specialises in offering expert guidance during the design of the health economics component of clinical trials. This encompasses the creation of tools for capturing resource utilisation, formulation of a health economics analysis plan that seamlessly integrates with the statistical analysis protocol, and the composition of study protocol and amendments of such for submission to regulators. Following the data locking phase, our proficient team can analyse patient-level data, adeptly performing survival analyses, micro- and macro-costing evaluations, addressing missing data concerns, and conducting multi-country assessments.